Numerous EGFR monoclonal antibodies or EGFR tyrosine kinase inhibitors (Meluch et al., 2010; Sutter et al., 2010) have been used alone or in combination with chemotherapy, radiotherapy or chemoradiotherapy to treat esophageal cancer, but the results have been disappointing (Ren et al., 2018). Here, EGFR is linked to esophageal cancer.